Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Terminated PHASE1 INTERVENTIONAL NCT05901467

Recall by Genotype: Neuropeptide Stimulation

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The objective of this protocol is to assess response to kisspeptin and gonadotropin-releasing hormone (GnRH) stimulation testing as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals who carry variants in genes related to infertility.

Detailed Description

Assignment: All study subjects will undergo the same interventions. Individuals at high risk for infertility (i.e., carry variants in genes related to infertility) will be compared to controls (i.e., those who do not carry variants in genes related to infertility). Delivery of Interventions: * Prior to the inpatient study visit, the subjects will undergo a review of their medical history, physical exam, and screening laboratories. * On the day of the study, the subjects will have an intravenous (IV) line placed and * Undergo up to q10 min blood sampling x 12 hours * Receive a single kisspeptin IV bolus at hour 8 * Receive a single GnRH IV bolus at hour 11

Interventions

Name: kisspeptin 112-121
Type: DRUG
Description: One IV bolus of kisspeptin 112-121
Name: GnRH
Type: DRUG
Description: One IV bolus of gonadotropin-releasing hormone

Primary Outcomes

Measure: Endogenous LH Pulse Amplitude
TimeFrame: Hours 0-8
Description: Average amplitude of LH pulses at baseline
Measure: Kisspeptin-induced LH Pulse Amplitude
TimeFrame: Hours 8-11
Description: Amplitude of LH pulse in response to kisspeptin

Trial Information

NCT ID

NCT05901467

Status

Terminated

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Stephanie B. Seminara, MD

Last Updated

December 15, 2025